Pethidine dose and female sex as risk factors for nausea after esophagogastroduodenoscopy
- PMID: 30487674
- PMCID: PMC6252297
- DOI: 10.3164/jcbn.18-5
Pethidine dose and female sex as risk factors for nausea after esophagogastroduodenoscopy
Abstract
Nausea and vomiting after esophagogastroduodenoscopy have not been studied in detail. The aim of this study was to evaluate the risk factors for post-endoscopic nausea. We performed a case-control study at the Toyoshima Endoscopy Clinic. Eighteen patients with post-endoscopic nausea and 190 controls without post-endoscopic nausea were analyzed. We conducted univariate and multivariate logistic regression analyses with respect to patient age; sex; body height; body weight; the use of psychotropic drugs as baseline medications; and the dosing amounts of midazolam, pethidine, flumazenil and naloxone. On univariate analysis, post-endoscopic nausea was significantly related with patient age (odds ratio = 0.946); female sex (odds ratio = 10.85); body weight (odds ratio = 0.975); and the dose per kg body weight of pethidine (odds ratio = 53.03), naloxone (odds ratio = 1.676), and flumazenil (odds ratio = 1.26). On multivariate analysis, the dose per kg body weight of pethidine (odds ratio = 21.67, p = 0.004) and female sex (odds ratio = 13.12, p = 0.047) were the factors independently associated with post-endoscopic nausea. The prevalence of nausea after esophagogastroduodenoscopy was 0.49% (18/3,654). In conclusion, post-endoscopic nausea was associated with the dose of pethidine and female sex.
Keywords: endoscopy; nausea; pethidine.
Conflict of interest statement
During the last two years, HS received scholarship funds for the research from Astellas Pharm Inc., Astra-Zeneca K.K., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd. and Zeria Pharmaceutical Co. Ltd., and received service honoraria from Astellas Pharm Inc., Astra-Zeneca K.K., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Zeria Pharmaceutical Co. Ltd. TK received scholarship funds for the research from Astellas Pharm Inc., Astra-Zeneca K.K., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Tanabe Mitsubishi Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Kyorin Pharmaceutical Co. Ltd., and received service honoraria from Astellas Pharm Inc., Eisai Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Tanabe Mitsubishi Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Miyarisan Pharmaceutical Co. Ltd. and Zeria Pharmaceutical Co. Ltd.. NY received scholarship funds for the research from Takeda Pharmaceutical Co., Ltd., Eisai Co., Kaigen Pharm Co., Ltd., Boston Scientific Japan K.K., Nihon Pharmaceutical Co., Ltd., Hoya Corporation and Otsuka Pharmaceutical Co. Ltd. The funding source had no role in the design, practice or analysis of this study. There are no other conflicts of interests for this article.
Similar articles
-
Adverse events associated with bidirectional endoscopy with midazolam and pethidine.J Clin Biochem Nutr. 2020 Jan;66(1):78-81. doi: 10.3164/jcbn.19-73. Epub 2019 Oct 30. J Clin Biochem Nutr. 2020. PMID: 32001961 Free PMC article.
-
Risk Factors for Prolonged Hospital Stay after Endoscopy.Clin Endosc. 2021 Nov;54(6):851-856. doi: 10.5946/ce.2020.292. Epub 2021 Mar 16. Clin Endosc. 2021. PMID: 33721977 Free PMC article.
-
Causative factors of discomfort in esophagogastroduodenoscopy: A large-scale cross-sectional study.World J Gastrointest Endosc. 2020 Apr 16;12(4):128-137. doi: 10.4253/wjge.v12.i4.128. World J Gastrointest Endosc. 2020. PMID: 32341749 Free PMC article.
-
Paradoxical reaction to midazolam in patients undergoing endoscopy under sedation: Incidence, risk factors and the effect of flumazenil.Dig Liver Dis. 2014 Aug;46(8):710-5. doi: 10.1016/j.dld.2014.04.007. Epub 2014 Jun 2. Dig Liver Dis. 2014. PMID: 24893689
-
[Utility of routine use of reversion after sedation in outpatient colonoscopy].Gastroenterol Hepatol. 2005 Jan;28(1):10-4. doi: 10.1157/13070377. Gastroenterol Hepatol. 2005. PMID: 15691462 Clinical Trial. Spanish.
Cited by
-
Comparison of propofol-based sedation and midazolam sedation in pediatric bidirectional endoscopy conducted by pediatric gastroenterologists.DEN Open. 2024 Jun 14;5(1):e391. doi: 10.1002/deo2.391. eCollection 2025 Apr. DEN Open. 2024. PMID: 38881579 Free PMC article.
-
Propofol for gastrointestinal endoscopy.United European Gastroenterol J. 2018 Jul;6(6):801-805. doi: 10.1177/2050640618767594. Epub 2018 Mar 22. United European Gastroenterol J. 2018. PMID: 30023057 Free PMC article. Review.
-
Increasing trend of Helicobacter pylori-uninfected gastric cancer without gastric atrophy.J Clin Biochem Nutr. 2022 Nov;71(3):245-248. doi: 10.3164/jcbn.22-56. Epub 2022 Aug 4. J Clin Biochem Nutr. 2022. PMID: 36447484 Free PMC article.
-
Small-caliber endoscopes are more fragile than conventional endoscopes.Endosc Int Open. 2019 Dec;7(12):E1729-E1732. doi: 10.1055/a-1036-6186. Epub 2019 Dec 10. Endosc Int Open. 2019. PMID: 31828209 Free PMC article.
-
Simple feedback of colonoscopy performance improved the number of adenomas per colonoscopy and serrated polyp detection rate.Endosc Int Open. 2021 Jul;9(7):E1032-E1038. doi: 10.1055/a-1393-5469. Epub 2021 Jun 17. Endosc Int Open. 2021. PMID: 34222627 Free PMC article.
References
-
- Wu Y, Zhang Y, Hu X, Qian C, Zhou Y, Xie J. A comparison of propofol vs. dexmedetomidine for sedation, haemodynamic control and satisfaction, during esophagogastroduodenoscopy under conscious sedation. J Clin Pharm Ther. 2015;40:419–425. - PubMed
-
- Cao X, White PF, Ma H. An update on the management of postoperative nausea and vomiting. J Anesth. 2017;31:617–626. - PubMed